Synthetic lipo-MDP analogs as mucosal adjuvants for animal vaccines

随着细菌对抗生素耐药性的增加正在成为一个世界性的问题，迫切需要减少兽医动物中抗生素的使用。由于缺乏安全和有效的佐剂，开发在大型动物身上触发长期免疫的无针头和成本效益疫苗具有挑战性。礼来克里克疫苗(LCV)公司正在开发对粘膜疫苗特别有用的新疫苗配方。与LCV合作，我们将研究一组结构定义的佐剂的潜力，这些佐剂能够通过与称为NOD2的特定受体分子相互作用来激活免疫系统。在化学合成这些化合物后，将在体外和体内研究中对它们的佐剂活性进行评估。这项研究有望为进一步开发提供新的疫苗佐剂候选。拟议的研究还将促进两国之间建立研究合作 申请者和LCV，并在开发兽医保健产品方面产生新的知识产权。研究成果最终可能转化为加拿大的重大经济和社会效益。

As the rise of bacterial resistance to antibiotics is becoming a worldwide problem, there is an urgent need for reducing antibiotic use in veterinary animals. The development of needle-free and cost-effective vaccines that trigger long-lasting immunity in large animals is challenging partly due to the lack of safe and potent adjuvants. Lilly Creek Vaccine (LCV) Inc. is developing new vaccine formulations that are particularly useful for mucosal vaccination. In partnership with LCV, we are going to study the potential of a group of structurally-defined adjuvants that are able to activate the immune system by interacting with a certain receptor molecule known as NOD2. After the chemical synthesis of these compounds, they will be evaluated for adjuvant activity in both in vitro and in vivo studies. The research is expected to provide new vaccine adjuvant candidates for further development. The proposed research will also facilitate the establishment of research collaboration between the applicant and LCV and generate new intellectual properties in developing veterinary health care products. The research outcome may eventually translate into significant economic and social benefits to Canada.